Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosensor Technology Enables Rapid Detection of Flu Virus

By LabMedica International staff writers
Posted on 12 Jun 2017
A research team has developed a voltage-sensor for early detection of influenza virus A (H1N1) that is almost 100 times more sensitive than conventional tests, and can distinguish between human and avian strains.

Researchers at Tokyo Medical and Dental University (TMDU; Tokyo, Japan) developed the sensor for early detection of even very low virus concentrations. More...
Such early-stage diagnosis is crucial for averting a potential pandemic outbreak, as antiviral medication must be administered in a timely fashion. Conventional tests for detecting the flu virus are often slow and expensive, and can miss early viral infections. In contrast, the new biosensor measures tiny changes in voltage in an electrically conductive polymer to quickly detect virus concentrations almost 100 times smaller than the limit of currently available kits.

Conductive polymers are a class of carbon-based molecules that conduct electricity, but can also be used in biological environments. Biomolecules can be easily attached to the polymers, allowing them to bind with specific targets. In this study, poly(3,4-ethylenedioxythiophene) (PEDOT) was modified with a functional group that binds with the H1N1 human influenza virus, but not avian influenza strains.

“Conducting polymers have several advantages over inorganic counterparts,” explained corresponding author Yuji Miyahara, “These include the ability to conduct both electrical and ionic carriers, mechanical flexibility, low cytotoxicity, low-cost production by casting or printing, and tunable properties via chemical synthesis or doping.”

To construct the biosensor, the polymer film was placed between two electrodes. When a solution containing H1N1, which carries a tiny positive charge on its exterior shell, was added, some of the viruses stuck to the polymer and increased the voltage measured by the electrodes. This electrical method allows the sensor to detect the presence of miniscule amounts of the virus. Viral loads are often measured in hemagglutination units (HAU). The new sensor can detect viral concentrations as small as 0.013 HAU. By comparison, commercially available kits that use immunochromatographic tests only work for concentrations greater than about 1.13 HAU.

“The device is a good candidate for wearable monitoring and point-of-care testing,” added study coauthor Shoji Yamaoka.

The study, by Hai W et al, was published April 5, 2017, in the journal ACS Applied Materials & Interfaces.

Related Links:
Tokyo Medical and Dental University


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.